Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jon Oliverio

Podiatrist Norton, OH Doctor of Podiatric Medicine

NPI 1710985163 CMS profile 169123

1193 Norton Ave, Suite D, Norton, OH 44203

Open in the dashboard

General payments

$5,625

159 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jon Oliverio of Norton, OH is reported in the CMS Open Payments database as having received $5,625 across 159 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $115 5
2024 General $287 9
2023 General $44 2
2022 General $182 9
2021 General $1,022 50
2020 General $597 40
2019 General $3,378 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jon Oliverio
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Jon Oliverio were reported at $115. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Jon Oliverio Podiatrist median Middle half National median
2019 $3,378 $196 $72–$601 $163
2020 $597 $118 $38–$335 $114
2021 $1,022 $169 $57–$573 $132
2022 $182 $220 $74–$782 $149
2023 $44 $208 $71–$635 $160
2024 $287 $237 $87–$681 $164
2025 $115 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Organogenesis Inc. $3,462 29 payments
  2. Smith+Nephew, Inc. $681 64 payments
  3. Melinta Therapeutics, Inc. $548 21 payments
  4. PolyNovo North America LLC $155 6 payments
  5. MIMEDX Group, Inc. $123 1 payment
  6. Treace Medical Concepts, Inc. $55 2 payments
  7. Medline Industries, Inc. $48 3 payments
  8. Integra LifeSciences Corporation $46 2 payments
  9. Alfasigma USA, Inc. $44 3 payments
  10. Paratek Pharmaceuticals, Inc. $39 2 payments
  11. Other $423 26 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,823 5 payments
  2. Food and Beverage $2,802 154 payments
Products named General payments · program years 2019–2025
  1. Apligraf $2,823 5 payments
  2. Puraply/Affinity/NuTech $2,823 5 payments
  3. Dermagraft $2,823 5 payments
  4. Puraply $489 17 payments
  5. Orbactiv $382 15 payments
  6. GRAFIX PL Other Advanced Wound Management $251 12 payments
  7. Kimyrsa $211 9 payments
  8. Baxdela $166 6 payments
  9. NOVOSORB BTM $155 6 payments
  10. GRAFIX PL Other Advanced Wound Management $130 15 payments
  11. Other $1,174 87 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

538

Median for Podiatry: 160

Drug cost

$7,236

Median for Podiatry: $2,368

Branded share of claims

21.7%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ciclopirox Ciclopirox Olamine Brand 47 $1,420
Neomycin-Polymyxin-Hc Neomycin/Polymyxin B/Hydrocort Brand 21 $1,137
Pentoxifylline Generic 19 $863
Fluocinonide Generic 23 $848
Cephalexin Generic 88 $569
Ammonium Lactate Generic 33 $554
Mupirocin Generic 87 $534
Doxycycline Hyclate Generic 43 $332
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 38 $306
Gabapentin Generic 30 $241

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$64,777

Medicare's payments for the services billed

Medicare patients

263

Average age 75

Services billed

1,272

140 women, 123 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Diabetes 45%
Chronic kidney disease 37%
Ischemic heart disease 36%
Heart failure 27%
Atrial fibrillation 27%
Depression 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

159 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record